News

Empty gabapentin capsules spur recall


 

References

Following the discovery of capsules found to be empty, Aurobindo Pharma USA has initiated a recall of the epilepsy treatment gabapentin, the company announced Nov. 21.

The company is voluntarily recalling lot GESB14011-A of 100-count bottles of 300 mg gabapentin, which have an expiration date of December 2015. The product also is used to manage postherpetic neuralgia.

The Food and Drug Administration noted that the empty capsules could result in missed doses, potentially resulting in no effect, short-term efficacy reduction, short-term withdrawal effect, or status epilepticus that could be life threatening.

gtwachtman@frontlinemedcom.com

Recommended Reading

Prescription opioids linked to majority of opioid overdoses
MDedge Neurology
Brain changes identified in chronic fatigue syndrome
MDedge Neurology
Comborbidities likely explain opioid + sleep apnea mortality risk
MDedge Neurology
Opioids for Chronic Noncancer Pain—Risks Outweigh Benefits
MDedge Neurology
Naloxone Is Frequently Prescribed for Patients With Chronic Pain Taking Opioids
MDedge Neurology
Amitriptyline May Be Effective for Chronic Low Back Pain
MDedge Neurology
Current use of COX-2 inhibitors linked to increased mortality after ischemic stroke
MDedge Neurology
Topiramate
MDedge Neurology
FDA approves extended-release hydrocodone with abuse-deterrent features
MDedge Neurology
Can Medical Marijuana Help Pediatric Patients?
MDedge Neurology